U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Issue: Mar/Apr 2017 - Volume 21, Number 2
View All Articles in Issue
Abstract: The reasons for which pharmaceutical compounding is the focus of intense state and federal scrutiny are now well known. Compounders are faced with an ever-increasing need to prove, by objective standards, the safety, purity, and potency of the formulations they dispense. They must also demonstrate their compliance with regulations often based on current good compounding practices designed for the pharmaceutical industry. In the U.S. today, rigorous unannounced state and federal inspections of compounding facilities are occurring more and more frequently. To achieve a successful outcome, communicating clearly and effectively with inspectors and having ready access to the information they request are as critical as proving compliance. This article describes the author’s experience with an unannounced United States Food and Drug Administration inspection of his 503A compounding facility and his response to the findings. Readers will learn what to expect during such an inspection, how to prepare for that event, and how to achieve an excellent outcome. Those who would like more information about any of the topics presented are invited to contact the author at the address provided at the close of this article.
Related Keywords: Doug Yoch, PharmD, U.S. Food and Drug Administration, FDA, pharmacy inspection, 503A sterile compounding pharmacies, pharmacy standards, pharmacy regulation, inspectors, documentation, recordkeeping, standard operating procedure, gap analysis
Related Categories: LEGAL, STERILE PREPARATIONS, QUALITY CONTROL
Download in electronic PDF format for $35